The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

The latest announcement is out from Merck & Company ( (MRK) ).

- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

HHS Secretary Robert F. Kennedy Jr. formally accepted recommendations that would require all vaccine manufacturers to ...

The federal government is recommending flu vaccines remove the preservative thimerosal after Health and Human Services ...

Health and Human Services Secretary Robert F. Kennedy Jr. ordered that thimerosal, a mercury-based preservative, be removed ...

Merck & Co., Inc. (NYSE:MRK) noted that ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, simplifying dosing logistics.

Enflonsia is a component of Merck & Co., Inc. (NYSE:MRK)’s expanding vaccine portfolio, which, together with its oncology and other pharmaceutical operations, has grown in importance as a ...